Polyclonal anti–T-cell antibody that depletes recipient lymphocytes to facilitate donor cell engraftment.
Polyclonal anti-thymocyte IgG that binds multiple T-cell surface antigens and depletes lymphocytes via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, leading to profound T-cell immunosuppression to facilitate donor cell engraftment.
rATG antibodies bind CD6 on T cells and mediate complement-dependent lysis and Fc-dependent ADCC, with additional apoptosis, leading to depletion of CD6+ lymphocytes.
Polyclonal anti–T-cell antibody that depletes recipient lymphocytes to facilitate donor cell engraftment.
Polyclonal anti-thymocyte IgG that binds multiple T-cell surface antigens and depletes lymphocytes via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, leading to profound T-cell immunosuppression to facilitate donor cell engraftment.
Polyclonal anti-thymocyte IgG binds CD7 on T cells and induces complement-mediated lysis, Fc-mediated ADCC, and apoptosis, depleting CD7+ cells.
Intravenous humanized anti-HER2 monoclonal antibody that binds the HER2 extracellular domain to inhibit signaling and mediates antibody-dependent cellular cytotoxicity via Fcγ receptor–bearing immune cells.
Humanized anti-HER2 (ERBB2) monoclonal IgG1 that binds the HER2 extracellular domain, blocking HER2 signaling and receptor dimerization, and engaging Fc-gamma receptor-bearing immune cells to mediate antibody-dependent cellular cytotoxicity against HER2-overexpressing tumor cells.
Trastuzumab binds HER2 on target cells and its Fc engages FcγR-expressing immune cells (e.g., NK cells) to mediate antibody-dependent cellular cytotoxicity; may also contribute via complement and signaling blockade–induced apoptosis.
Polyclonal anti–T-cell antibody that depletes recipient lymphocytes to facilitate donor cell engraftment.
Polyclonal anti-thymocyte IgG that binds multiple T-cell surface antigens and depletes lymphocytes via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, leading to profound T-cell immunosuppression to facilitate donor cell engraftment.
rATG contains antibodies that bind CD28 on T cells and induce complement-dependent lysis and Fc-mediated ADCC, with additional apoptosis, directly depleting CD28+ cells.
Polyclonal anti–T-cell antibody that depletes recipient lymphocytes to facilitate donor cell engraftment.
Polyclonal anti-thymocyte IgG that binds multiple T-cell surface antigens and depletes lymphocytes via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, leading to profound T-cell immunosuppression to facilitate donor cell engraftment.
rATG contains antibodies that bind CD25 on T cells; Fc engagement activates complement (CDC) and recruits effector cells for ADCC, also inducing apoptosis, thereby depleting CD25+ cells.